This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Confirms AstraZeneca Interest

NEW YORK (The Deal) -- New York pharmaceuticals giant Pfizer (PFE - Get Report) on Monday said it was considering making a renewed run at AstraZeneca AZN to strengthen its cancer treatments after a failed January approach and as rivals successfully expand their oncology businesses.

Pfizer said it hoped to offer AstraZeneca investors a "significant premium" after trying to lure AstraZeneca into talks with a 4,661 pence ($78.51) per-share offer, which it said represented a 30% premium for shareholders at the time. It envisages an offer in both cash and shares but said it may alter the final terms.

Although investors already pushed up the stock 7.9% last week amid reports of Pfizer's interest, AstraZeneca shares leapt 11.5%, or 481.50 pence, to 4,656.50 pence in Monday morning trading in London. That values the company at 58.8 billion pounds.

"We believe patients all over the globe would benefit from our shared commitment to R&D, which is critical to the future success of the pharmaceutical industry, in the form of potential new therapies that help to fight some of the world's most feared diseases, such as cancer," said Pfizer CEO and chairman Ian Read in a statement.

Must Read: Meda Rejects New Mylan Takeover Proposal

Drug companies the world over kicked off a consolidation a decade ago that has included a series of multi-billion dollar deals as manufacturers try to offset the loss of patents on blockbuster drugs. They've also spent to buy drug development companies and sold off less profitable assets.

Last week, Basel's Novartis (NVS - Get Report) agreed to buy the oncology business of GlaxoSmithKline (GSK - Get Report), adding impetus to Pfizer's ambitions. Novartis also wants to sell its vaccine business to GlaxoSmithKline and link its over-the-counter business with the buyer's. Novartis also announced a deal to sell its animal health division to Indianapolis-based Eli Lilly (LLY - Get Report).

In another recent oncology-related deal, Germany's Bayer in December agreed to pay nearly $3 billion for Norwegian partner Algeta, which recently began marketing a prostate cancer treatment.

AstraZeneca has reportedly tapped Goldman, Sachs & Co. and Morgan Stanley to review any approaches.

Despite investor enthusiasm, analysts aren't so taken with Pfizer's plans.

"I view a takeover of AstraZeneca by the U.S. drug company exceptionally skeptically," wrote Deutsche Bank AG analyst Mark Clark in a note. He has a hold rating on AstraZeneca shares. Clark said AstraZeneca's oncology pipeline is too young to be of much help to Pfizer in the short term.

Meanwhile, Pfizer said combining with AstraZeneca would give it "industry-leading" treatments for various lung cancers as well as AstraZeneca's Faslodex, a breast cancer treatment in Phase 3 -- the final stage -- trials.

Pfizer said it also saw promise by combining their experimental oncology drugs and hoped to save money by combining non-overlapping activities.

A combined Pfizer and AstraZeneca would be based and listed in New York but have management in both New York and London, the company said.

AstraZeneca refused to comment.

Pfizer is taking financial advice from Bank of America Merrill Lynch's Fares Noujaim, Adrian Mee, Michael Findlay and Geoff Iles; a Guggenheim Securities LLC team of Alan Schwartz, Ken Springer and Jim Ferency; and JPMorgan Securities LLC's Steve Frank, Laurence Hollingworth, Mark Breuer and Christopher Dickinson.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AZN $28.96 0.00%
GSK $42.91 0.00%
LLY $75.53 0.00%
NVS $75.97 0.00%
PFE $32.71 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs